Skip to main content
SpringerLink
Log in

PD-1/PD-L1 inhibitors increase risk of hepatitis

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. immune checkpoint inhibitors

Reference

  • Guo X, et al. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. European Journal of Clinical Pharmacology : 8 Jun 2020. Available from: URL: http://doi.org/10.1007/s00228-020-02903-2

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

PD-1/PD-L1 inhibitors increase risk of hepatitis. Reactions Weekly 1809, 9 (2020). https://doi.org/10.1007/s40278-020-79793-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-79793-1

Search

Navigation